Intellia, Novartis form five-year CRISPR/Cas9 collaboration
Over the next five years, Intellia Therapeutics Inc. and Novartis AG’s Novartis Institutes for BioMedical Research Inc. agreed to apply CRISPR/Cas9 gene editing and repair technologies ex vivo to chimeric antigen receptor T (CART) cells and hematopoietic stem cells (HSCs) for the treatment of cancers and hematological disorders.
- Gene Therapy, Cell Therapy
- Large Molecule
Drug Discovery Tools
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Product or Technology Swap
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.